Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

Key facts

Study ID

NCT00618709

Run by

Kythera Biopharmaceuticals

People needed

24

Starts

2008-01-01

Expected to finish

2009-01-01

Last updated by the study team

2014-05-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or nonpregnant females
• Age 18 to 65
• Sufficient submental fat for injections
• Signed informed consent

You may not qualify if…

• Prior interventions in the chin or neck area
• History or presence of drug or alcohol abuse
• Treatment with an investigational agent within 30 days before the dose

Where it is running

• MDS Pharma Services — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.